Australia · Delayed Price · Currency is AUD Nexsen Company Description
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications.
The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones.
The company was incorporated in 2021 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mark Muzzin |
Contact Details
Address: 4 Bridge Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9174 5388 |
| Website | nexsen.bio |
Stock Details
| Ticker Symbol | NXN |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000418782 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Reece O'Connell | Executive Chairman |
| Mark Anthony Muzzin B.A. | Founder, MD, Advisory Board Member and Director |
| Richard Mark Jarvis | Chief Financial Officer |
| Dr. Sanje Mahasivam | Research Team Leader and Chief Technology Officer |
| Prof. Vipul Bansal | Chief Innovation Officer and Advisory Board Chair |
| Sonny Didugu | Company Secretary |